Adiponectin inhibits oxidized low density lipoprotein-induced increase in matrix metalloproteinase 9 expression in
Maryam Saneipour1, Keihan Ghatreh-Samani2, Esfandiar Heydarian3
1MSc Student, Clinical Biochemistry Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Background:
High expression of matrix metalloproteinase 9 (MMP9) during vascular injury and inflammation plays an important role in atherosclerotic plaque formation and rupture. In the process of atherosclerosis, oxidized low-density lipoprotein (oxLDL) upregulates MMP9 in human aortic vascular smooth muscle cells (HA/VSMCs). Adiponectin is an adipose tissue-derived hormone that has been shown to exert anti-atherogenic and anti-inflammatory effects. The aim of this study was to investigate the effect of adiponectin on MMP9 expression under pathogenic condition created by oxLDL in HA/VSMCs.
Methods:
In this experimental study, HA/VSMC were stimulated with oxLDL alone and in the presence of adiponectin for 24 and 48 h. The expression of MMP9 gene was determined by real-time polymerase chain reaction method. The protein level of this gene was investigated by western blotting technique.
Results:
An oxLDL increased MMP9 expression 2.16 ± 0.24- and 3.32 ± 0.25-fold after 24 and 48 h, respectively and adiponectin decreased oxLDL-induced MMP9 expression in a time-dependent manner.
Conclusion:
These results show that adiponectin changes extracellular matrix by reducing MMP9 mRNA and protein, therefore, may stabilize lesions and reduce atheroma rupture.
Insights
Adiponectin reduces matrix metalloproteinase 9 (MMP9) expression in human aortic vascular smooth muscle cells stimulated by oxidized low-density lipoprotein (oxLDL). This finding suggests adiponectin may stabilize atherosclerotic lesions and prevent rupture.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Atherosclerosis Research
Background:
- Matrix metalloproteinase 9 (MMP9) is upregulated during vascular injury and inflammation, contributing to atherosclerotic plaque development and rupture.
- Oxidized low-density lipoprotein (oxLDL) elevates MMP9 expression in human aortic vascular smooth muscle cells (HA/VSMCs).
- Adiponectin, an adipokine, possesses anti-atherogenic and anti-inflammatory properties.
Purpose of the Study:
- To investigate the impact of adiponectin on MMP9 expression in HA/VSMCs under oxLDL-induced conditions.
- To determine if adiponectin can counteract the effects of oxLDL on MMP9.
Main Methods:
- HA/VSMCs were treated with oxLDL alone and in combination with adiponectin for 24 and 48 hours.
- MMP9 gene expression was quantified using real-time polymerase chain reaction (RT-PCR).
- MMP9 protein levels were assessed via western blotting.
Main Results:
- Oxidized low-density lipoprotein (oxLDL) significantly increased MMP9 expression by 2.16-fold at 24 hours and 3.32-fold at 48 hours.
- Adiponectin treatment demonstrably reduced oxLDL-induced MMP9 expression in a time-dependent manner.
- Both mRNA and protein levels of MMP9 were affected by adiponectin.
Conclusions:
- Adiponectin effectively reduces MMP9 mRNA and protein levels in the context of oxLDL stimulation.
- By modulating MMP9, adiponectin may alter the extracellular matrix.
- These findings suggest adiponectin's potential role in stabilizing atherosclerotic lesions and reducing the risk of plaque rupture.
More Related Videos
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
08:41Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
Published on: June 3, 2019
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:28Nitric Oxide Signaling Pathway
01:23Role of Matrix Metalloproteases in Degradation of ECM